Entrar Registro gratuito

Neovacs S.A Ret. no patrimônio

Qual é o Ret. no patrimônio de Neovacs S.A?

O Ret. no patrimônio de Neovacs S.A. é -11.05%

Qual é a definição de Ret. no patrimônio?



O retorno sobre o patrimônio é uma medida da lucratividade de um negócio em relação ao valor contábil do patrimônio líquido. É calculado pela divisão do lucro líquido do exercício pelo total do patrimônio líquido.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. no patrimônio de empresas na Setor Health Care em EURONEXT em comparação com Neovacs S.A

O que Neovacs S.A faz?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Empresas com ret. no patrimônio semelhantes a Neovacs S.A